-->
404
نعتذر , لا نستطيع ايجاد الصفحة المطلوبة
  • العودة الى الصفحة الرئيسية
  • الاثنين، 9 نوفمبر 2020

    Carcinoid syndrome

    Carcinoid syndrome

    Carcinoid syndrome

    D E FI N I T ION 

    Constellation of symptoms caused by systemic release of humoral factors
    (biogenic amines, polypeptides, prostaglandins) from carcinoid tumours.

    AETIOLOGY 

    Carcinoid tumours are slow-growing neuroendocrine tumours mostly derived
    from serotonin-producing enterochromaffin cells. They produce secretory products
    such as serotonin, histamine, tachykinins, kallikrein and prostaglandin. May be classified into
    fore-, mid- or hindgut tumours. 75–80%of patients with the carcinoid syndrome have small
    bowel carcinoids. Common sites for carcinoid tumours include appendix and rectum, where
    they are often benign and non-secretory. Also found in other parts of large intestine,
    stomach, thymus, bronchus and other organs. Hormones released into the portal circulation
    are metabolized in the liver. Thus symptoms typically do not appear until there are hepatic
    metastases (resulting in the secretion of tumour products into the hepatic veins), or release
    into the systemic circulation from bronchial or extensive retroperitoneal tumours.

    E P IDEMIOLOGY

     Rare, annual UK incidence is one in 1 000 000. Asymptomatic carcinoid
    tumours are more common and may be an incidental finding after rectal biopsy or
    appendectomy. Ten percent of patients with multiple endocrine neoplasia (MEN) type 1
    have carcinoid tumours.

    H ISTORY

     Paroxysmal flushing, diarrhoea, crampy abdominal pain, wheeze, sweating,
    palpitations.

    EXAMINA T I ON

     Facial flushing, telangiectasia, wheeze.
    Right-sided heart murmurs: Tricuspid stenosis, regurgitation or pulmonary stenosis.
    Nodular hepatomegaly in cases of metastatic disease.
    Carcinoid crisis: Profound flushing, bronchospasm, tachycardia and fluctuating blood
    pressure.

    INVE S T I G A T IONS 

    24-h urine collection: 5-HIAA levels (a metabolite of serotonin, false
    positive with high intake of certain fruit/drugs e.g. bananas and avocados, caffeine,
    paracetamol).
    Blood: Plasma chromogranin A and B, fasting gut hormones.
    CT or MRI scan: To localizes the tumour.
    Radioisotope scan: Radiolabelled somatostatin analogue (e.g. indium-111 octreotide) helps
    localize tumour.
    Investigations for MEN-1: (see footnote to Hyperparathyroidism).

    MANAGEMENT 

    Carcinoid crisis: Octreotide infusion, also IV antihistamine and
    hydrocortisone.
    Multidisciplinary approach (endocrinologists/gastroenterologists, oncologists, radiologists
    and surgeons).
    Advice: Avoid precipitating factors e.g. alcohol, strenuous exercise.
    Somatostatin analogues (e.g. octreotide) inhibit hormone release and tumour growth.
    Radiolabelled octreotide may be beneficial (receptor-targeted therapy).
    Interferon-a: May be given on its own or added to long-acting somatostatin analogues if the
    patient is not responding to the maximum dosage of somatostatin analogues.
    Supportive: Ondansetron and cyproheptadine (5-HT antagonists) can alleviate symptoms,
    rehydration (for diarrhoea), antiemetics and anti-diarrhoeal treatment (codeine,
    loperamide).
    Surgery: Should be considered for resectable nodal or hepatic metastasis, extraintestinal
    (bronchial and ovarian) carcinoids. Small intestinal carcinoids may be resected even in the
    presence of metastases, to prevent fibrosing mesenteritis. Valve surgery for symptomatic
    carcinoid heart disease. A potential peri-operative carcinoid crisis should be prevented by
    prophylactic treatment with octreotide
    Carcinoid syndrome (continued)
    Hepatic artery embolization: For patients with non-resectable multiple and hormone secreting
    tumours. Two types: particle and chemoembolization.

    COMPL I C A T IONS

     Electrolyte imbalance (secondary to diarrhoea), metastases, bowel
    obstruction (due to fibrosis near a gut primary), tricuspid and pulmonary valve stenosis with
    consequent right heart failure, pellagra: dermatitis, glossitis, diarrhoea, dementia (due to
    niacin deficiency caused by diversion of dietary tryptophan for the synthesis of large amounts
    of serotonin).

    P ROGNOS I S

     Median survival is usually 5–10 years but can range up to 20 years.
    Earlier detection and treatment should improve quality of life and survival.
    ثم اثناء كتابة المقالة نحدد مكان الاعلان عن طريق وضع الكود التالى

    ***********************


    ***********************

    .جعفر جاسم طالب كلية صيدلة من دوله العراق يهتم بتقديم كل ما هو جديد وحصري في عالم الطب و الاخبار العامه ، وهدف هو الارتقاء بالمحتوى العربي و الطبي >

    By : PH.Jafar Jassim

    هناك 6 تعليقات:

    " جميع الحقوق محفوظة ل مدونه صيدلاني
    تصميم : jafar jasim